Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 51
Filtrar
1.
Ann Med Surg (Lond) ; 85(5): 1480-1485, 2023 May.
Artigo em Inglês | MEDLINE | ID: mdl-37229062

RESUMO

New generation devices that combine high-flow insufflation with smoke aspiration using continuous gas recirculation ]so-called Insufflator/aspirator systems (IAS)] have recently been developed to generate pneumoperitoneum. The use of an IAS could have an impact on surgical compared to conventional insufflation systems (CIS). The present study aimed to compare the clinical effectiveness/safety, healthorganizational, and pathological/oncological outcomes of the CIS versus IAS during robot-assisted radical prostatectomy (RARP). Methods: Comparative retrospective cohort study including patients with non-metastatic prostate cancer treated with RARP by four expert surgeons at a robotic referral centre between January 2020 and December 2021. A CIS was used until 15 March 2021, and the IAS thereafter. Data were extracted from the Institutional Review Board-approved (#1064) retro and prospective institutional database. Results: The final analysis included 299 patients (143 CIS; 156 IAS). We found no statistically significant differences in demographic data and preoperative results, allowing adequate group comparison. The rate of complications of any degree (9.1% and 1.9%, P<0.05) and major complications (4.2% and 0.6%, P<0.05) were lower in the IAS group. Accordingly, the hospital stay was shorter in the IAS group (P<0.05); however, the small size of this statistically significant difference probably lacks clinical value (1.9±1.6 vs. 1.6±0.8 days). There was no significant difference in surgical time, bleeding, pathological findings, or oncological results. Conclusions: Data from this large group of patients showed that the rate of overall complications, the rate of major complications, and the length of stay were lower in the IAS group. Implementing the IAS in RARP patients increased the occurrence of SCE and affected our daily practice of transversus abdominis plane block. Interpretation of the results should be made with caution since the design of this study did not allow for the identification of a causal relationship.

2.
Gac Med Mex ; 159(2): 135-141, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37094244

RESUMO

BACKGROUND: Spotted fever rickettsiosis is a serious disease with a high mortality rate if not timely detected. OBJECTIVE: To describe the characteristics of patients hospitalized for spotted fever rickettsiosis, as well as the risk factors associated with poor prognosis. MATERIAL AND METHODS: Data from medical records of patients hospitalized between August 2012 and July 2022 were collected. Variables were analyzed using Mann-Whitney's U-test, Fisher's exact test, and univariate or multivariate logistic regression analysis. RESULTS: Twenty-six patients were analyzed, among which a mortality of 57.6% was identified. In the between-group comparison, platelet count was lower in non-survivors (16.0 × 103/µL vs. 25.9 × 103/µL, p = 0.031). The percentage of surviving patients who received treatment more than 72 hours after fever onset was 45.5% (five patients) vs. 86.7% of non-survivors (13 patients) (p = 0.034). Receiving treatment 72 hours after fever onset increased by 7.09 times the probability of a fatal outcome (OR = 8.09, 95% CI = 1.1-55.8, p = 0.034). CONCLUSIONS: Starting adequate treatment 72 hours after the onset of fever may be an important risk factor for mortality, hence the importance of timely diagnosis and appropriate treatment of this disease.


ANTECEDENTES: La rickettsiosis de fiebre manchada es una enfermedad grave y con alta tasa de letalidad si no se identifica oportunamente. OBJETIVO: Describir las características de los pacientes hospitalizados por rickettsiosis de fiebre manchada, así como los factores de riesgo asociados a mal pronóstico. MATERIAL Y MÉTODOS: Se recabaron los datos del expediente clínico de pacientes hospitalizados entre agosto de 2012 y julio de 2022. Las variables se analizaron mediante prueba U de Mann-Whitney, prueba exacta de Fisher y regresión logística univariada y multivariada. RESULTADOS: Se analizaron 26 pacientes, en quienes se identificó una mortalidad de 57.6 %. En la comparación entre grupos, el número de plaquetas fue menor en los no supervivientes (16.0 × 103/µL versus 25.9 × 103/µL, p = 0.031). El porcentaje de pacientes supervivientes que recibieron tratamiento más de 72 horas después del inicio de la fiebre fue 45.5 % (cinco pacientes) versus 86.7 % de los no supervivientes (13 pacientes), p = 0.034. Recibir tratamiento después de 72 horas del inicio de la fiebre incrementó 7.09 veces la probabilidad de desenlace fatal (RM = 8.09, IC 95 % = 1.1-55.8, p = 0.034). CONCLUSIONES: Iniciar tratamiento adecuado posterior a 72 horas del inicio de la fiebre podría ser un factor de riesgo de mortalidad, de ahí que la importancia del diagnóstico oportuno y tratamiento adecuado de esta enfermedad.


Assuntos
Infecções por Rickettsia , Rickettsiose do Grupo da Febre Maculosa , Humanos , Criança , México , Hospitais Pediátricos , Atenção Secundária à Saúde , Rickettsiose do Grupo da Febre Maculosa/diagnóstico , Infecções por Rickettsia/diagnóstico
3.
Gac. méd. Méx ; 159(2): 138-144, mar.-abr. 2023. tab
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1430397

RESUMO

Resumen Antecedentes: La rickettsiosis de fiebre manchada es una enfermedad grave y con alta tasa de letalidad si no se identifica oportunamente. Objetivo: Describir las características de los pacientes hospitalizados por rickettsiosis de fiebre manchada, así como los factores de riesgo asociados a mal pronóstico. Material y métodos: Se recabaron los datos del expediente clínico de pacientes hospitalizados entre agosto de 2012 y julio de 2022. Las variables se analizaron mediante prueba U de Mann-Whitney, prueba exacta de Fisher y regresión logística univariada y multivariada. Resultados: Se analizaron 26 pacientes, en quienes se identificó una mortalidad de 57.6 %. En la comparación entre grupos, el número de plaquetas fue menor en los no supervivientes (16.0 × 103/µL versus 25.9 × 103/µL, p = 0.031). El porcentaje de pacientes supervivientes que recibieron tratamiento más de 72 horas después del inicio de la fiebre fue 45.5 % (cinco pacientes) versus 86.7 % de los no supervivientes (13 pacientes), p = 0.034. Recibir tratamiento después de 72 horas del inicio de la fiebre incrementó 7.09 veces la probabilidad de desenlace fatal (RM = 8.09, IC 95 % = 1.1-55.8, p = 0.034). Conclusiones: Iniciar tratamiento adecuado posterior a 72 horas del inicio de la fiebre podría ser un factor de riesgo de mortalidad, de ahí que la importancia del diagnóstico oportuno y tratamiento adecuado de esta enfermedad.


Abstract Background: Spotted fever rickettsiosis is a serious disease with a high mortality rate if not timely detected. Objective: To describe the characteristics of patients hospitalized for spotted fever rickettsiosis, as well as the risk factors associated with poor prognosis. Material and methods: Data from medical records of patients hospitalized between August 2012 and July 2022 were collected. Variables were analyzed using Mann-Whitney's U-test, Fisher's exact test, and univariate or multivariate logistic regression analysis. Results: Twenty-six patients were analyzed, among which a mortality of 57.6% was identified. In the between-group comparison, platelet count was lower in non-survivors (16.0 × 103/µL vs. 25.9 × 103/µL, p = 0.031). The percentage of surviving patients who received treatment more than 72 hours after fever onset was 45.5% (five patients) vs. 86.7% of non-survivors (13 patients) (p = 0.034). Receiving treatment 72 hours after fever onset increased by 7.09 times the probability of a fatal outcome (OR = 8.09, 95% CI = 1.1-55.8, p = 0.034). Conclusions: Starting adequate treatment 72 hours after the onset of fever may be an important risk factor for mortality, hence the importance of timely diagnosis and appropriate treatment of this disease.

4.
Gac Med Mex ; 2023 Mar 01.
Artigo em Espanhol | MEDLINE | ID: mdl-36857754

RESUMO

Background: Spotted fever rickettsiosis is a serious disease with a high mortality rate if not timely detected. Objective: To describe the characteristics of patients hospitalized for spotted fever rickettsiosis, as well as the risk factors associated with poor prognosis. Material and methods: Data from medical records of patients hospitalized between August 2012 and July 2022 were collected. Variables were analyzed using Mann-Whitney's U-test, Fisher's exact test, and univariate or multivariate logistic regression analysis. Results: Twenty-six patients were analyzed, among which a mortality of 57.6% was identified. In the between-group comparison, platelet count was lower in non-survivors (16.0 × 103/µL vs. 25.9 × 103/µL, p = 0.031). The percentage of surviving patients who received treatment more than 72 hours after fever onset was 45.5% (five patients) vs. 86.7% of non-survivors (13 patients) (p = 0.034). Receiving treatment 72 hours after fever onset increased by 7.09 times the probability of a fatal outcome (OR = 8.09, 95% CI = 1.1-55.8, p = 0.034). Conclusions: Starting adequate treatment 72 hours after the onset of fever may be an important risk factor for mortality, hence the importance of timely diagnosis and appropriate treatment of this disease.


Antecedentes: La rickettsiosis de fiebre manchada es una enfermedad grave y con alta tasa de letalidad si no se identifica oportunamente. Objetivo: Describir las características de los pacientes hospitalizados por rickettsiosis de fiebre manchada, así como los factores de riesgo asociados a mal pronóstico. Material y métodos: Se recabaron los datos del expediente clínico de pacientes hospitalizados entre agosto de 2012 y julio de 2022. Las variables se analizaron mediante prueba U de Mann-Whitney, prueba exacta de Fisher y regresión logística univariada y multivariada. Resultados: Se analizaron 26 pacientes, en quienes se identificó una mortalidad de 57.6 %. En la comparación entre grupos, el número de plaquetas fue menor en los no supervivientes (16.0 × 103/µL versus 25.9 × 103/µL, p = 0.031). El porcentaje de pacientes supervivientes que recibieron tratamiento más de 72 horas después del inicio de la fiebre fue 45.5 % (cinco pacientes) versus 86.7 % de los no supervivientes (13 pacientes), p = 0.034. Recibir tratamiento después de 72 horas del inicio de la fiebre incrementó 7.09 veces la probabilidad de desenlace fatal (RM = 8.09, IC 95 % = 1.1-55.8, p = 0.034). Conclusiones: Iniciar tratamiento adecuado posterior a 72 horas del inicio de la fiebre podría ser un factor de riesgo de mortalidad, de ahí que la importancia del diagnóstico oportuno y tratamiento adecuado de esta enfermedad.

5.
Gac Med Mex ; 157(2): 154-159, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34270536

RESUMO

BACKGROUND AND OBJECTIVE: Diseases of the respiratory system represent one of the leading causes of medical care and antibiotic prescriptions. Currently, new technologies are used for the diagnosis of respiratory diseases of viral origin, such as the FilmArray Respiratory Panel®, approved in 2012 by the FDA. The purpose of this study was to identify the correlation between the diagnosis and treatment of respiratory tract infections and the result of the polymerase chain reaction test for respiratory viruses. MATERIAL AND METHODS: The study is of a retrospective, cross-sectional, descriptive type. One-hundred and thirty-four patients who underwent a viral panel for respiratory viruses, which was positive for one or more viruses, were included. For all cases, the positive results of said test and the treatment received by patients were analyzed. RESULTS: Of the patients who underwent nasopharyngeal aspirate during hospitalization, 58 % received antibiotic treatment at admission, 13 % received combined treatment (antibiotic + antiviral), 27 % of the patients received symptomatic treatment since admission and 2 % did it with antivirals. After receiving a positive result for respiratory viruses, 38 % continued with antibiotics, 30 % with antibiotics and antivirals, 13.8 % were managed only with antivirals and 18.2 % with symptomatic treatment. CONCLUSION: Despite the global alert regarding antimicrobial resistance, patients continue to be treated with antibiotics, due to a situation that we ignore, but that is believed to be influenced by several factors.


ANTECEDENTES Y OBJETIVO: Las enfermedades del sistema respiratorio son causa frecuente de prescripción de antibióticos. Actualmente se emplean nuevas tecnologías para su diagnóstico como el FilmArray Respiratory Panel. El objetivo de este estudio es identificar la correlación entre el diagnóstico y tratamiento de infecciones de vías respiratorias con el resultado de PCR para virus respiratorios. MATERIAL Y MÉTODOS: Estudio descriptivo, transversal, retrospectivo, se incluyeron 134 pacientes atendidos en el Hospital Christus Muguerza en Saltillo, Coahuila. Para todos los casos se analizaron los resultados del panel y el tratamiento que recibieron los pacientes. RESULTADOS: El 58 % recibió tratamiento antibiótico a su ingreso, el 13 % tratamiento combinado (antibiótico + antiviral), 27 % recibió tratamiento sintomático y el 2 % fue tratado con antiviral de primera instancia. Posterior al resultado el 38 % continuó con antibiótico, el 30 % con antibiótico y antiviral, 13.8 % se manejó con antiviral y el 18.2 % con tratamiento sintomático. CONCLUSIÓN: A pesar de la alerta mundial por la resistencia a los antimicrobianos se sigue tratando a los pacientes con antibióticos, por una situación que se cree está influenciada por varios factores.


Assuntos
Antibacterianos/uso terapêutico , Antivirais/uso terapêutico , Reação em Cadeia da Polimerase Multiplex , Infecções Respiratórias/virologia , Viroses/diagnóstico , Doença Aguda , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Estudos Transversais , Feminino , Hospitais Privados , Humanos , Lactente , Masculino , México , Pessoa de Meia-Idade , Infecções Respiratórias/diagnóstico , Infecções Respiratórias/tratamento farmacológico , Estudos Retrospectivos , Viroses/tratamento farmacológico , Viroses/virologia , Adulto Jovem
6.
Nat Genet ; 53(7): 1006-1021, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-34211179

RESUMO

SPTBN1 encodes ßII-spectrin, the ubiquitously expressed ß-spectrin that forms micrometer-scale networks associated with plasma membranes. Mice deficient in neuronal ßII-spectrin have defects in cortical organization, developmental delay and behavioral deficiencies. These phenotypes, while less severe, are observed in haploinsufficient animals, suggesting that individuals carrying heterozygous SPTBN1 variants may also show measurable compromise of neural development and function. Here we identify heterozygous SPTBN1 variants in 29 individuals with developmental, language and motor delays; mild to severe intellectual disability; autistic features; seizures; behavioral and movement abnormalities; hypotonia; and variable dysmorphic facial features. We show that these SPTBN1 variants lead to effects that affect ßII-spectrin stability, disrupt binding to key molecular partners, and disturb cytoskeleton organization and dynamics. Our studies define SPTBN1 variants as the genetic basis of a neurodevelopmental syndrome, expand the set of spectrinopathies affecting the brain and underscore the critical role of ßII-spectrin in the central nervous system.


Assuntos
Genes Dominantes , Predisposição Genética para Doença , Variação Genética , Transtornos do Neurodesenvolvimento/genética , Espectrina/genética , Animais , Estudos de Associação Genética/métodos , Heterozigoto , Humanos , Camundongos , Transtornos do Neurodesenvolvimento/diagnóstico , Fenótipo , Espectrina/metabolismo
7.
Stem Cell Res ; 54: 102421, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-34130156

RESUMO

The generation of induced pluripotent stem cells (iPSCs) from healthy individuals is an invaluable resource as reference control in disease modeling and drug discovery. This paper details the reprogramming of peripheral blood mononuclear cells (PBMCs) isolated from a healthy 27 years-old male using non-integration technology. The derived iPSCs displayed typical pluripotent stem cell morphology, the capacity to differentiate into the three germ layers, and normal karyotype. This iPSC line will be used as a reference control to study the Cerebral Cavernous Malformation disease mechanism.


Assuntos
Hemangioma Cavernoso do Sistema Nervoso Central , Células-Tronco Pluripotentes Induzidas , Adulto , Diferenciação Celular , Reprogramação Celular , Camadas Germinativas , Hemangioma Cavernoso do Sistema Nervoso Central/genética , Humanos , Leucócitos Mononucleares , Masculino
8.
Gac Med Mex ; 157(1): 102-106, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34125805

RESUMO

INTRODUCTION: In the context of the COVID-19 pandemic, there is concern regarding the impact of the influenza season. OBJECTIVE: To analyze the impact of influenza immunization history on patients with SARS-CoV-2 infection. METHODS: Patients older than 18 years with COVID-19, registered between March and August 2020, were included. Data were analyzed using Fisher's exact test and Student's t-test. To evaluate the impact on mortality, a logistic regression model was used; the relationship between the percentage of patients who received the influenza vaccine and mortality was determined with Pearson's correlation coefficient. RESULTS: 16,879 participants were included; 17 % had a history of influenza vaccination. Mortality was lower in the group with a history of vaccination (3.5 % vs. 7 %, p < 0.0001). The vaccination rate had an inverse relationship with the mortality rate (Pearson's r: -0.922, p = 0.026). CONCLUSIONS: Previous influenza immunization was an independent protective factor for mortality in patients with COVID-19. Although further studies are needed to determine a causal relationship, it would be reasonable to increase influenza immunization in the general population.


INTRODUCCIÓN: En el contexto de la pandemia de COVID-19 existe inquietud en cuanto al impacto de la temporada de influenza. OBJETIVO: Analizar el impacto del antecedente de inmunización contra influenza en pacientes con infección por SARS-CoV-2. MÉTODOS: Se incluyeron pacientes mayores de 18 años con COVID-19, registrados entre marzo y agosto de 2020. Los datos fueron analizados mediante las pruebas exacta de Fisher y t de Student. Para evaluar el impacto en la mortalidad se utilizó un modelo de regresión logística; la relación entre el porcentaje de pacientes a quienes se aplicó la vacuna contra la influenza y la mortalidad fue determinada con el coeficiente de correlación de Pearson. RESULTADOS: Se incluyeron 16 879 participantes; 17 % tuvo antecedente de vacunación contra influenza. La mortalidad fue menor en el grupo con historia de vacunación (3.5 % versus 7 %, p < 0.0001). El porcentaje de vacunación presentó una relación inversa con el porcentaje de mortalidad (r de Pearson ­ 0.922, p = 0.026). CONCLUSIONES: La inmunización contra la influenza fue un factor protector independiente de mortalidad en pacientes con COVID-19. Aunque son necesarios más estudios para determinar la relación causal, será razonable incrementar la inmunización contra influenza en la población general.


Assuntos
COVID-19/mortalidade , Vacinas contra Influenza , Vacinação/estatística & dados numéricos , Adolescente , Adulto , COVID-19/prevenção & controle , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Adulto Jovem
9.
Diversitas perspectiv. psicol ; 17(1): 3-20, Jan.-June 2021. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1375306

RESUMO

Resumen El objetivo del estudio fue explorar la estructura factorial de la Brief Self-Control Scale (BSCS; Tangney, Baumeister y Boone, 2004) aplicada como autorreporte a una muestra de 151 participantes en Colombia (edad promedio de 8.2 años, 50.33 % niñas y 49.66 % niños) y 115 participantes en Chile (edad promedio de 7.3 años, 53.04 % niñas y 49.95 % niños). La escala también fue respondida a modo de heterorreporte por 80 madres de los participantes colombianos y las 115 madres de los participantes chilenos. El Análisis Factorial Exploratorio (AFE) arrojó soluciones bifactoriales en todas las muestras y reportó valores de consistencia interna aceptables, aunque la composición de los factores difirió notablemente entre países y entre madres e hijos(as). Los hallazgos se discuten en términos de las diferencias culturales, en la socialización del autocontrol y el desarrollo de la capacidad de autorregulación en los primeros años de la escuela primaria. Se concluye que la medición del autoncontrol en este grupo etáreo mediante la BSCS requiere ajustes.


Abstract The aim of this study was to explore the factor structure of the Brief Self-Control Scale (BSCS; Tangney, Baumeister and Boone, 2004) used as self-report with a sample of 151 participants in Colombia (mean age 8.2 years, 50.33 % girls and 49.66 % boys) and 115 participants in Chile (mean age 7.3 years, 53.04 % girls and 49.95 % boys). The scale was also answered as a hetero-report by 80 mothers of the Colombian participants and the 115 mothers of the Chilean participants. The Exploratory Factor Analysis (EFA) revealed bifactor solutions in all samples and reported acceptable internal consistency values, although the composition of the factors differed markedly between countries and between mothers and children. The findings are discussed in terms of cultural differences, in the socialization self-control and development of self-regulation skills in the early elementary school years. According to these findings, the measurement of self-control in this age group using the BSCS requires adjustments.

10.
Gac. méd. Méx ; 157(2): 160-165, mar.-abr. 2021. graf
Artigo em Espanhol | LILACS | ID: biblio-1279096

RESUMO

Resumen Antecedentes y objetivo: Las enfermedades del sistema respiratorio son causa frecuente de prescripción de antibióticos. Actualmente se emplean nuevas tecnologías para su diagnóstico como el FilmArray Respiratory Panel. El objetivo de este estudio es identificar la correlación entre el diagnóstico y tratamiento de infecciones de vías respiratorias con el resultado de PCR para virus respiratorios. Material y métodos: Estudio descriptivo, transversal, retrospectivo, se incluyeron 134 pacientes atendidos en el Hospital Christus Muguerza en Saltillo, Coahuila. Para todos los casos se analizaron los resultados del panel y el tratamiento que recibieron los pacientes. Resultados: El 58 % recibió tratamiento antibiótico a su ingreso, el 13 % tratamiento combinado (antibiótico + antiviral), 27 % recibió tratamiento sintomático y el 2 % fue tratado con antiviral de primera instancia. Posterior al resultado el 38 % continuó con antibiótico, el 30 % con antibiótico y antiviral, 13.8 % se manejó con antiviral y el 18.2 % con tratamiento sintomático. Conclusión: A pesar de la alerta mundial por la resistencia a los antimicrobianos se sigue tratando a los pacientes con antibióticos, por una situación que se cree está influenciada por varios factores.


Abstract Background and objective: Respiratory system diseases represent one of the leading cause of prescription of antibiotics. At present, new technologies for the diagnosis are being used, including the FilmArray Respiratory Panel. The objective was to identify the correlation between the diagnosis and treatment of respiratory tract infections with the result of PCR for respiratory viruses. Material and methods: Descriptive, cross-sectional, restrospective study. 134 patients were included treated at the Christus Muguerza Hospital in Saltillo, Coahuila. For all cases, the positive results of this test and the treatment patients received were analyzed. Results: 58 % received antibiotic treatment at admission, 13 % received combined treatment (antibiotic + antiviral), 27 % received symptomatic treatment since their admission and 2 % whit antiviral. After receiving a positive result for respiratory viruses, 38 % continued with antibiotics, 30 % with antibiotics and antivirals, 13.8 % only managed with antivirals and 18.2% with symptomatic treatment. Conclusion: Although we are currently on global alert for resistance to antibiotics, there is a lack of awareness about the prescription of antibiotics, due to a situation which is believed to be influenced by several factors.


Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Adulto Jovem , Antivirais/uso terapêutico , Infecções Respiratórias/virologia , Viroses/diagnóstico , Reação em Cadeia da Polimerase Multiplex , Antibacterianos/uso terapêutico , Infecções Respiratórias/diagnóstico , Infecções Respiratórias/tratamento farmacológico , Viroses/tratamento farmacológico , Viroses/virologia , Doença Aguda , Estudos Transversais , Estudos Retrospectivos , Hospitais Privados , México
11.
Gac. méd. Méx ; 157(1): 108-112, ene.-feb. 2021. tab, graf
Artigo em Espanhol | LILACS | ID: biblio-1279083

RESUMO

Resumen Introducción: En el contexto de la pandemia de COVID-19 existe inquietud en cuanto al impacto de la temporada de influenza. Objetivo: Analizar el impacto del antecedente de inmunización contra influenza en pacientes con infección por SARS-CoV-2. Métodos: Se incluyeron pacientes mayores de 18 años con COVID-19, registrados entre marzo y agosto de 2020. Los datos fueron analizados mediante las pruebas exacta de Fisher y t de Student. Para evaluar el impacto en la mortalidad se utilizó un modelo de regresión logística; la relación entre el porcentaje de pacientes a quienes se aplicó la vacuna contra la influenza y la mortalidad fue determinada con el coeficiente de correlación de Pearson. Resultados: Se incluyeron 16 879 participantes; 17 % tuvo antecedente de vacunación contra influenza. La mortalidad fue menor en el grupo con historia de vacunación (3.5 % versus 7 %, p < 0.0001). El porcentaje de vacunación presentó una relación inversa con el porcentaje de mortalidad (r de Pearson –0.922, p = 0.026). Conclusiones: La inmunización contra la influenza fue un factor protector independiente de mortalidad en pacientes con COVID-19. Aunque son necesarios más estudios para determinar la relación causal, será razonable incrementar la inmunización contra influenza en la población general.


Abstract Introduction: In the context of the COVID-19 pandemic, there is concern regarding the impact of the influenza season. Objective: To analyze the impact of influenza immunization history on patients with SARS-CoV-2 infection. Methods: Patients older than 18 years with COVID-19, registered between March and August 2020, were included. Data were analyzed using Fisher’s exact test and Student’s t-test. To evaluate the impact on mortality, a logistic regression model was used; the relationship between the percentage of patients who received the influenza vaccine and mortality was determined with Pearson’s correlation coefficient. Results: 16,879 participants were included; 17 % had a history of influenza vaccination. Mortality was lower in the group with a history of vaccination (3.5 % vs. 7 %, p < 0.0001). The vaccination rate had an inverse relationship with the mortality rate (Pearson’s r: -0.922, p = 0.026). Conclusions: Previous influenza immunization was an independent protective factor for mortality in patients with COVID-19. Although further studies are needed to determine a causal relationship, it would be reasonable to increase influenza immunization in the general population.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Adulto Jovem , Vacinas contra Influenza , Vacinação/estatística & dados numéricos , COVID-19/mortalidade , Estudos Retrospectivos , COVID-19/prevenção & controle
13.
Index enferm ; 29(1/2): 13-17, ene.-jun. 2020. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-197419

RESUMO

OBJETIVO PRINCIPAL: conocer la percepción del colectivo transexual acerca de la atención sanitaria recibida. METODOLOGÍA: se realizó un estudio cualitativo siguiendo un diseño fenomenológico. Para la recogida de datos y su posterior análisis, se realizaron siete entrevistas semiestructuradas individuales y una entrevista grupal. La información recogida fue transcrita y categorizada resguardando el rigor científico mediante el proceso de triangulación. RESULTADOS PRINCIPALES: las principales percepciones del colectivo transexual con respecto a la atención sanitaria recibida son la aceptación, falta de capacitación adicional sobre transexualidad del personal sanitario, no informar adecuadamente al colectivo transexual y demora o tiempo de espera. CONCLUSION PRINCIPAL: se han superado ciertas barreras a las que se enfrenta el colectivo transexual en el sistema sanitario. Sin embargo, el nivel de formación del personal con respecto a la transexualidad no es adecuado. Este estudio propone una mejora en la formación de los profesionales sanitarios, a la vez que subraya la necesidad revisar y aumentar las investigaciones sobre el tratamiento hormonal que recibe el colectivo transexual


OBJECTIVE: knowing the perception on health care received in transsexual adults. METHODS: a qualitative study with phenomenological approach, using seven individual semi-structured interviews and one group interview in order to collect data and carry out the analysis of the same. The information was transcribed and categorized preserving the scientific rigor by means of the triangulation process. RESULTS: the following perceptions of the transsexual collective regarding the healthcare received stand out acceptance, lack of additional training on transsexualism, not adequately inform the transsexual collective and delay or waiting time. CONCLUSIONS: Although certain barriers to the transsexual collective have already been overcomed in the health system, the level of training of the health professionals regarding transsexualism is not adequate. Therefore, this study proposes an improvement in the training of health professionals, while it emphasizes the need for more research on the hormonal treatment they receive


Assuntos
Humanos , Masculino , Feminino , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Pessoas Transgênero/estatística & dados numéricos , Percepção , Atenção à Saúde , Atenção Primária à Saúde , Identidade de Gênero , Serviços de Saúde , Pessoal de Saúde/educação
14.
Med. clín (Ed. impr.) ; 154(7): 248-253, abr. 2020. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-190907

RESUMO

OBJETIVO: Determinar si un régimen medicamentoso más simple en pacientes pluripatológicos se asocia con la supervivencia. MÉTODOS: En un estudio de cohortes multicéntrico se incluyeron pacientes pluripatológicos hospitalizados en servicios de medicina interna entre el 1 de marzo y el 30 de junio de 2011. Se excluyeron los reingresos y los fallecidos. Se recogieron datos de edad, sexo, residencia, enfermedad, índices de Charlson, Barthel y Lawton-Brody, Short Portable Mental State Questionnaire, escala de Gijón, número de ingresos en el año previo, delirio, necesidad de cuidador e índice PROFUND. Se calculó la complejidad terapéutica con el Medication Regimen Complexity Index. Se hizo un seguimiento de 4 años. Para determinar los factores asociados con la mortalidad por todas las causas se construyó un modelo de regresión de Cox. RESULTADOS: Se incluyeron 233 pacientes pluripatológicos con una edad media de 79,8 (8,6) años. La puntuación media en el Medication Regimen Complexity Index fue 32 (15,2). A los 4 años fallecieron 161 (72,2%) pacientes, 36 con régimen de medicación más simple. La edad (HR 1,060; IC95% 1,032-1,089; p < 0,001), las neoplasias (HR 2,477; IC95% 1,564-3,923; p < 0,001) y el número de ingresos en el año previo (HR 1,251; IC95% 1,100-1,423; p = 0,001) se asociaron de forma independiente con la mortalidad, y la puntuación del índice de Barthel (HR 0,991; IC95% 0,983-0,998; p < 0,001) y la simplicidad del régimen de medicación (HR 0,634; IC95% 0,414-0,970; p = 0,036) con menor mortalidad. CONCLUSIONES: En los pacientes pluripatológicos los regímenes de medicación más simples se asocian con una menor mortalidad


OBJECTIVE: To determine if a more simplified medication regimen is associated with survival in polypathological patients. METHODS: Multicentre cohort study. We included polypathological patients admitted to internal medicine wards between March 1st and June 30rd, 2011. Patients that died during admission and readmissions were excluded. Data were collected about age, gender, home, comorbidity, Charlson, Barthel and Lawton-Brody indexes, Short Portable Mental State Questionnaire, socio-familial Gijón scale, admissions in the previous year, delirium, need of a caregiver and PROFUND index. The therapy complexity was measured with the Medication Regimen Complexity Index. The follow-up lasted 4-years. To determine the factors associated with mortality we performed a Cox proportional regression model. RESULTS: Overall 223 polypathological patients were included, with a mean age of 79.8 (8.6) years. Mean score in Medication Regimen Complexity Index was 32.0 (15.2). After 4 years, 161 (72.2%) patients died, 36 with a more simplified medication regimen. Age (HR 1.060, 95%CI 1.032-1.089; P<.001), neoplasms (HR 2.477, 95%CI 1.564-3.923; P<.001), and the number of admissions in the previous year (HR 1.251, 95%CI 1.100-1.423; P=.001) were independently associated with 4-year mortality, and Barthel index score (HR .991, 95%CI .983-0.998; P<.001) and a more simplified medication regimen (HR 0.634 95%CI 0.414-.970; p=.036) with lower mortality. CONCLUSIONS: In polypathological patients, the more simplified medication regimens are associated with a lower mortality


Assuntos
Humanos , Feminino , Idoso , Masculino , Idoso de 80 Anos ou mais , Sobrevivência , Estudos de Coortes , Conduta do Tratamento Medicamentoso/normas , Adesão à Medicação , Polimedicação , Múltiplas Afecções Crônicas/tratamento farmacológico , Hospitalização , Conduta do Tratamento Medicamentoso/organização & administração , Estudos Prospectivos , 28599 , Análise de Variância , Readmissão do Paciente
15.
Med Clin (Barc) ; 154(7): 248-253, 2020 04 10.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-31455520

RESUMO

OBJECTIVE: To determine if a more simplified medication regimen is associated with survival in polypathological patients. METHODS: Multicentre cohort study. We included polypathological patients admitted to internal medicine wards between March 1st and June 30rd, 2011. Patients that died during admission and readmissions were excluded. Data were collected about age, gender, home, comorbidity, Charlson, Barthel and Lawton-Brody indexes, Short Portable Mental State Questionnaire, socio-familial Gijón scale, admissions in the previous year, delirium, need of a caregiver and PROFUND index. The therapy complexity was measured with the Medication Regimen Complexity Index. The follow-up lasted 4-years. To determine the factors associated with mortality we performed a Cox proportional regression model. RESULTS: Overall 223 polypathological patients were included, with a mean age of 79.8 (8.6) years. Mean score in Medication Regimen Complexity Index was 32.0 (15.2). After 4 years, 161 (72.2%) patients died, 36 with a more simplified medication regimen. Age (HR 1.060, 95%CI 1.032-1.089; P<.001), neoplasms (HR 2.477, 95%CI 1.564-3.923; P<.001), and the number of admissions in the previous year (HR 1.251, 95%CI 1.100-1.423; P=.001) were independently associated with 4-year mortality, and Barthel index score (HR .991, 95%CI .983-0.998; P<.001) and a more simplified medication regimen (HR 0.634 95%CI 0.414-.970; p=.036) with lower mortality. CONCLUSIONS: In polypathological patients, the more simplified medication regimens are associated with a lower mortality.


Assuntos
Hospitalização , Medicina Interna , Idoso , Estudos de Coortes , Comorbidade , Humanos , Modelos de Riscos Proporcionais
17.
Bol. méd. Hosp. Infant. Méx ; 76(6): 281-286, nov.-dic. 2019.
Artigo em Espanhol | LILACS | ID: biblio-1089145

RESUMO

Resumen Introducción: En México, cuando se inició la aplicación de la vacuna PCV13 (neumocócica conjugada), se cubría el 70.6% de los serotipos causantes de enfermedad invasiva por neumococo en menores de 5 años. Después de varios años, los casos de enfermedad causada por los serotipos incluidos en la vacuna han disminuido; sin embargo, se ha producido un reemplazo por los serotipos no incluidos en la vacuna. Caso clínico: Se presentan tres casos de pacientes pediátricos que desarrollaron enfermedad invasiva por serotipos no incluidos en la PCV13: uno con meningitis y bacteriemia (serotipo 15C) y dos con neumonía, uno de ellos complicado con derrame (serotipo 35B). Los pacientes fueron atendidos en un hospital pediátrico en Saltillo, Coahuila, durante el periodo de 2015 a 2018. Conclusiones: Resulta alarmante que se presenten tres casos graves por serotipos de Streptococcus pneumoniae no incluidos en la PCV13 en un solo hospital pediátrico en el norte del país. Este es un fenómeno que esta sucediendo a escala nacional e internacional: un incremento de casos de enfermedad invasiva por serotipos de neumococo no incluidos en la vacuna utilizada actualmente.


Abstract Background: In Mexico, 70.6% of serotypes causing invasive pneumococcal disease were covered since the application of the PCV13 vaccine in children under 5 years of age. After several years of immunization, cases of disease caused by the serotypes included in the vaccine have decreased. However, a replacement due to serotypes not included in the vaccine has been observed. Case report: Three cases of pediatric patients who developed invasive disease due to serotypes not included in PCV13 are described: one with meningitis and bacteremia (serotype 15C), and two with pneumonia, of which one complicated with effusion (serotype 35B). Patients were treated in a pediatric hospital in Saltillo, Coahuila, from 2015 to 2018. Conclusions: Three serious cases due to serotypes of Streptococcus pneumoniae not included in PCV13 were reported in a single pediatric hospital in a northern state of Mexico. This phenomenon is taking place nationwide and worldwide: an increase of cases of invasive disease due to pneumococcal serotypes not included in the vaccine currently used.


Assuntos
Pré-Escolar , Feminino , Humanos , Infecções Pneumocócicas/microbiologia , Streptococcus pneumoniae/classificação , Vacinas Pneumocócicas , Infecções Pneumocócicas/complicações , Infecções Pneumocócicas/tratamento farmacológico , Streptococcus pneumoniae/isolamento & purificação , Sorotipagem , Vacinas Conjugadas , México
18.
Reumatol. clín. (Barc.) ; 15(6): e114-e115, nov.-dic. 2019. tab
Artigo em Espanhol | IBECS | ID: ibc-189666

RESUMO

La enfermedad de Kawasaki (EK) es una vasculitis sistémica frecuente en niños menores de 5 años, involucra arterias coronarias y otros vasos de mediano calibre, además existe evidencia de lesión inflamatoria y proliferativa de la vía biliar e infiltración linfocitaria en el intersticio renal. Se presenta el caso de una niña de 9 años con fiebre de alto grado; desarrollando inyección conjuntival bilateral no purulenta, lengua «aframbuesada», eritema y descamación en dedos de manos y pies, síndrome colestásico, así como edema e incremento de azoados. La EK continúa siendo un reto diagnóstico para el pediatra. En todo paciente con síndrome febril, colestasis y daño renal agudo la EK debe considerarse como diagnóstico diferencial, aunque es necesario realizar más estudios para evaluar esta atípica asociación


Kawasaki disease (KD) is a systemic vasculitis frequent in children younger than 5 years of age. It involves coronary arteries and other medium-sized vessels. There also exists evidence of inflammatory and proliferative changes affecting the biliary tract and lymphocyte infiltration of the renal interstitial. We describe the case of a 9-year-old girl who developed high-grade fever, bilateral non-purulent conjunctivitis, «strawberry» tongue, desquamation of the fingers and toes, cholestatic syndrome, edema and elevated serum creatinine. KD is a diagnostic challenge for the pediatrician. In every patient with high-grade fever, cholestasis and acute kidney injury, KD should be included in the differential diagnosis, even though more research is necessary to evaluate this atypical association


Assuntos
Humanos , Feminino , Criança , Injúria Renal Aguda/etiologia , Colestase/etiologia , Síndrome de Linfonodos Mucocutâneos/complicações , Síndrome de Linfonodos Mucocutâneos/diagnóstico
19.
Asian Pac J Cancer Prev ; 20(11): 3385-3389, 2019 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-31759363

RESUMO

INTRODUCTION: An elevated serum PSA is the only biomarker routinely used in screening for prostate cancer to indicate a prostate biopsy. However, it is not specific for prostate cancer and the neutrophil/lymphocyte ratio has been suggested as an alternative. We present a prospective study of men with an elevated PSA and compare the neutrophil/lymphocyte ratio, free percent PSA, PSA density and the presence of circulating prostate cells to detect clinically significant prostate cancer at first biopsy. PATIENTS AND METHODS: Prospective study of consecutive men with a PSA 4-10 ng/ml referred for initial prostate biopsy, the results were compared with the neutrophil/lymphocyte ratio, free percent PSA and PSA density. Circulating prostate cells (CPCs) were detected using immunocytochemistry. The blood sample was taken immediately before the prostate biopsy. RESULTS: 1,223 men participated, 38% (467) of whom had prostate cancer detected, of these 322 were clinically significant. The area under the curves were for neutrophil/lymphocyte ratio, free percent PSA, PSA density and CPC detection were 0.570, 0.785, 0,620 and 0.844 respectively. Sensitivity/specificity were 0.388/0.685, 0.419/0.897, 0.598/0.624 and 0.966/0.786 respectively. The neutrophil/lymphocyte ratio did not differentiate between benign and malignant disease. CONCLUSIONS: The neutrophil/lymphocyte ratio did not discriminate between benign and malignant prostatic disease in patients with a PSA between 4-10ng/ml.


Assuntos
Linfócitos/patologia , Células Neoplásicas Circulantes/patologia , Neutrófilos/patologia , Antígeno Prostático Específico/metabolismo , Neoplasias da Próstata/patologia , Idoso , Biópsia/métodos , Humanos , Imuno-Histoquímica/métodos , Testes Imunológicos/métodos , Linfócitos/metabolismo , Masculino , Pessoa de Meia-Idade , Células Neoplásicas Circulantes/metabolismo , Neutrófilos/metabolismo , Estudos Prospectivos , Próstata/metabolismo , Próstata/patologia , Neoplasias da Próstata/metabolismo , Sensibilidade e Especificidade
20.
Bol Med Hosp Infant Mex ; 76(6): 281-286, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31769441

RESUMO

Background: In Mexico, 70.6% of serotypes causing invasive pneumococcal disease were covered since the application of the PCV13 vaccine in children under 5 years of age. After several years of immunization, cases of disease caused by the serotypes included in the vaccine have decreased. However, a replacement due to serotypes not included in the vaccine has been observed. Case report: Three cases of pediatric patients who developed invasive disease due to serotypes not included in PCV13 are described: one with meningitis and bacteremia (serotype 15C), and two with pneumonia, of which one complicated with effusion (serotype 35B). Patients were treated in a pediatric hospital in Saltillo, Coahuila, from 2015 to 2018. Conclusions: Three serious cases due to serotypes of Streptococcus pneumoniae not included in PCV13 were reported in a single pediatric hospital in a northern state of Mexico. This phenomenon is taking place nationwide and worldwide an increase of cases of invasive disease due to pneumococcal serotypes not included in the vaccine currently used.


Introducción: En México, cuando se inició la aplicación de la vacuna PCV13 (neumocócica conjugada), se cubría el 70.6% de los serotipos causantes de enfermedad invasiva por neumococo en menores de 5 años. Después de varios años, los casos de enfermedad causada por los serotipos incluidos en la vacuna han disminuido; sin embargo, se ha producido un reemplazo por los serotipos no incluidos en la vacuna. Caso clínico: Se presentan tres casos de pacientes pediátricos que desarrollaron enfermedad invasiva por serotipos no incluidos en la PCV13: uno con meningitis y bacteriemia (serotipo 15C) y dos con neumonía, uno de ellos complicado con derrame (serotipo 35B). Los pacientes fueron atendidos en un hospital pediátrico en Saltillo, Coahuila, durante el periodo de 2015 a 2018. Conclusiones: Resulta alarmante que se presenten tres casos graves por serotipos de Streptococcus pneumoniae no incluidos en la PCV13 en un solo hospital pediátrico en el norte del país. Este es un fenómeno que esta sucediendo a escala nacional e internacional: un incremento de casos de enfermedad invasiva por serotipos de neumococo no incluidos en la vacuna utilizada actualmente.


Assuntos
Infecções Pneumocócicas/microbiologia , Vacinas Pneumocócicas , Streptococcus pneumoniae/classificação , Pré-Escolar , Feminino , Humanos , México , Infecções Pneumocócicas/complicações , Infecções Pneumocócicas/tratamento farmacológico , Sorotipagem , Streptococcus pneumoniae/isolamento & purificação , Vacinas Conjugadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...